Wang, Jiangqin https://orcid.org/0000-0003-4643-3453
Yang, Chuanyan
Chang, Shenghai
Jiao, Dian
Lin, Jiahao
Yang, Xiaotong
Cai, Weijie
Ma, Demin https://orcid.org/0000-0002-2730-3680
Ding, Zhong Jie https://orcid.org/0000-0003-1518-5143
Huang, Jia
Huang, Jianhua
Fan, Minrui https://orcid.org/0009-0002-8375-6972
Hu, Meiqin https://orcid.org/0000-0002-3953-5868
Wang, Yong https://orcid.org/0000-0001-9156-0377
Xu, Haoxing https://orcid.org/0000-0003-3561-4654
Su, Nannan https://orcid.org/0000-0002-8737-0412
Guo, Jiangtao https://orcid.org/0000-0002-8850-286X
Article History
Received: 25 September 2025
Accepted: 14 May 2026
First Online: 10 June 2026
Competing interests
: H.X. is the scientific co-founder and a partial owner of Lysoway Therapeutics Inc. (Boston, MA). The other authors declare no competing interests.